News Does Roche have buyer's remorse for Flatiron takeover? Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.
News BMS strikes three-year cancer R&D deal with Flatiron Bristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and patient-focused.
News Pfizer might buy BMS for $130bn – but should it? Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face